|
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR. |
|
|
Honoraria - Celgene; Onyx |
Consulting or Advisory Role - Celgene; Onyx |
|
|
Honoraria - Celgene; Janssen; Millennium; Novartis; Onyx |
Consulting or Advisory Role - Celgene; Janssen; Millennium; Novartis; Onyx |
|
|
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Onyx |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Onyx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Onyx |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Onyx |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Onyx |
Research Funding - Takeda (Inst) |
|
|
Consulting or Advisory Role - Celgene; Janssen |
Speakers' Bureau - Celgene; Janssen |
|
|
Employment - GlaxoSmithKline |
Honoraria - Celgene; Chugai Pharma; Janssen; Millennium; Novartis; Onyx |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium; Novartis; Onyx |
Research Funding - Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Novartis |
|
|
Honoraria - Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Vesselina Goranova-Marinova |
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Onyx |
|
|
No Relationships to Disclose |